Lilly(Eli) & Company
NYSE: LLY
$915.04
+$10.07 (+1.1%)
Closing Price on September 19, 2024
LLY Chart and Intraday Price
LLY Company Data
| Asset Type | Stock |
| Exchange | NYSE |
| Currency | USD |
| Country | USA |
| Sector | LIFE SCIENCES |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Address | LILLY CORPORATE CTR, DROP CODE 1094, INDIANAPOLIS, IN, US |
| Fiscal Year End | December |
| Latest Quarter | 12/31/2023 |
| Market Cap | 743,142.26M USD |
| Shares Outstanding | 950,164,000 |
LLY Articles
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 586.36% and currently trading at $907.44. The company has been around since 1876 and the...
Published:
Last Updated:
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are for the next decade of growth.
Published:
Jim Cramer is probably the closest thing we have to stock market superstar influencer. The host of CNBC’s “Mad Money” show is entertaining and popular with a broad swath of investors who like...
Published:
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX), for example. Now trading at $57.80, we strongly believe it could easily rally...
Published:
As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin. Undoubtedly, several investment themes, including generative AI and...
Published:
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair. The drug discovery...
Published:
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry. The...
Published:
Unless you have been living under the rock, you’d have heard of Nvidia’s (NASDAQ: NVDA) success story. All investors want a bite of this big business and those who missed out are now trying to...
Published:
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to...
Published:
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive. Indeed, the growth various weight loss drugs have seen is notable, with GLP-1 agonists...
Published:
Remember when a stock becoming valued at $1 trillion was a big thing? The first company to do so was Apple (NASDAQ:AAPL) back in 2018. Now there are a half dozen trillion-dollar stocks. And while a...
Published:
The July Consumer Price Index (CPI) appears to progress towards the Federal Reserve’s 2% inflation target rate. Consumer prices have started cooling after rising a modest 2.9% in the 12 months...
Published:
Holding a promising future due to recent success in the obesity drug market, Eli Lilly (NYSE:LLY) appears to be bound for continued gains. An impressive move higher in LLY stock, with the company’s...
Published:
Long-term stocks, or those that are meant to be held for over a year, let investors ignore daily market fluctuations. Known as “sleep-at-night” stocks, they remain reliable in the face of...
Published:
Eli Lilly (NYSE: LLY) stock has been a winner for investors of late, owing largely to strong consumer demand for obesity drugs. Shares have ballooned by nearly 60% year-to-date, while investors have...
Published: